EP1934183A1 - Methods of preparing anhydrous aripiprazole form ii - Google Patents

Methods of preparing anhydrous aripiprazole form ii

Info

Publication number
EP1934183A1
EP1934183A1 EP06825291A EP06825291A EP1934183A1 EP 1934183 A1 EP1934183 A1 EP 1934183A1 EP 06825291 A EP06825291 A EP 06825291A EP 06825291 A EP06825291 A EP 06825291A EP 1934183 A1 EP1934183 A1 EP 1934183A1
Authority
EP
European Patent Office
Prior art keywords
aripiprazole
slurry
acetone
temperature
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06825291A
Other languages
German (de)
English (en)
French (fr)
Inventor
Hagit Eisen-Nevo
Zhanna Pavlov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP1934183A1 publication Critical patent/EP1934183A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention encompasses methods of preparing anhydrous aripiprazole Form II.
  • Schizophrenia is the most common type of psychosis caused by excessive neurotransmission activity of the dopaminergic nervous system in the central nervous system.
  • a number of drugs which block the neurotransmission of dopaminergic receptor in the central nervous system have been developed for use in treating schizophrenia.
  • drugs developed are phenothiazine-type compounds such as chlorpromazine, butyrophenone-type compounds such as haloperidol, and benzamide-type compounds such as sulpiride. These drugs improve so-called positive symptoms in the acute period of schizophrenia such as hallucinations, delusions, and excitations.
  • Aripiprazole is a pyschotropic drug that exhibits high affinity for dopamine D 2 and D 3 , serotonin 5-HT 1A and 5-HT 2A receptors; moderate affinity for dopamine D 4 , serotonin 5-HT 2 c and 5-HT 7 , ⁇ -adrenergic and histamine H 1 receptors; and moderate affinity for the serotonin reuptake site.
  • Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors.
  • the mechanism of action of aripiprazole, as with other drugs having efficacy in schizophrenia, is unknown. It has been proposed, however, that the efficacy of aripiprazole is mediated through a combination of partial agonist activity at D 2 and 5-HT 1 A receptors and antagonist activity at 5-HT 2A receptors.
  • Type-I aripiprazole crystals can be prepared by recrystallizing aripiprazole from an ethanol solution or by heating aripiprazole hydrate at 80°C.
  • Type-II aripiprazole crystals can be prepared by heating the Type-I crystals at 130°C to 140°C for 15 hours. This process is not easily applied to an industrial scale preparation of anhydride aripiprazole.
  • PCT publication WO 03/26659 discloses the preparation of anhydrous aripiprazole Type I and crystalline Forms A, B, C, D, E, F. and G.
  • the powder x-ray diffraction spectrum for aripiprazole Form C has characteristic peaks at 12.6°, 13.7°, 15.4°, 18.1°, 19.0°, 20.6°, 23.5°, and 26.4° 2-theta.
  • the process for preparing the crystalline forms comprises heating crystalline anhydrous aripiprazole.
  • the process is cumbersome because it requires crystalline anhydrous aripiprazole as the starting material.
  • the process can include drying or heating the aripiprazole which may affect the distribution of crystalline forms and/or crystalline purity, if drying causes crystalline transformation from one crystalline form to another.
  • the methods of the invention provide procedures that consistently and reproducibly yield Form II consistently to increase the arsenal of crystalline forms available to the skilled artisan in preparing pharmaceutical formulations.
  • One embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising slurrying aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry.
  • the method can further comprise seeding the slurry with aripiprazole Form II prior to the heating step.
  • Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising providing a mixture of aripiprazole in acetone; heating the mixture at a temperature of about 56 0 C; cooling the mixture to room temperature; maintaining the mixture at a temperature of about 4 0 C for about 15 hours to obtain anhydrous aripiprazole Form II; providing a slurry of starting aripiprazole in acetone; seeding the slurry with the anhydrous aripiprazole Form II obtained from the mixture; heating the slurry at a temperature of about 25°C to about 5O 0 C; and isolating aripiprazole Form II.
  • Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl- acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 45 0 C to about the reflux temperature; cooling the mixture to a temperature of about 1O 0 C to about -2O 0 C; maintaining the mixture for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonit
  • Another embodiment of the invention encompasses a method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
  • Figure 1 illustrates the powder X-ray diffraction pattern for Form II.
  • the process of the invention describes slurrying aripiprazole from a low boiling solvent such as acetone.
  • a low boiling solvent such as acetone.
  • the process is reproducible and consistent such that it can be applied in the large scale manufacture of crystalline aripiprazole.
  • the slurry in acetone reduces the amounts of solvent used during crystallization, thus yielding a significant economical and ecological advantage.
  • Aripiprazole Form II prepared by the method of the invention, is disclosed in WO 05/058835, hereby incorporated by reference. As disclosed therein, aripiprazole Form II is characterized by X-ray powder diffraction peaks at 16.5, 18.7, 21.9, 22.4 and 23.5 degrees two-theta ⁇ 0.2 degrees two-theta.
  • the aripiprazole crystalline Form II used for seeding can be made in situ or obtained as described in the PCT publication WO 05/058835.
  • Aripiprazole Form XII and Compound 2 are also disclosed in WO 05/058835.
  • aripiprazole Form XII is characterized by X-ray powder diffraction peaks at 17.4, 18.2, 19.7 and 24.5 degrees two-theta ⁇ 0.2 degrees two-theta; and aripiprazole compound 2 is characterized by X-ray powder diffraction peaks at 8.8, 14.5, 17.8, 20.5 and 22.2 degrees two-theta ⁇ 0.2 degrees two-theta.
  • the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising slurrying a starting aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl-acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the slurry; and isolating anhydrous aripiprazole Form II from the slurry.
  • the method can further comprise seeding the slurry with aripiprazole Form II prior to the heating step.
  • the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the aripiprazole.
  • the starting aripiprazole is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
  • the solvent is acetone.
  • the amount of the solvent should be sufficient to form a slurry with the aripiprazole.
  • the ratio of starting aripiprazole to acetone is about 3:1 to about 20:1 ml of acetone per gram of aripiprazole. More preferably, the ratio of starting aripiprazole to acetone is about 3:1 to about 6:1 ml of acetone to gram of aripiprazole.
  • 30 g of aripiprazole 90 to 180 mL of acetone can be used.
  • the slurry is heated to a temperature of about 25°C to about 5O 0 C. More preferably, the slurry is heated to a temperature of about 3O 0 C to about 5O 0 C.
  • the slurry is maintained at the temperature for at least 1 hour, preferably from about 2 hours to about 22 hours.
  • the anhydrous aripiprazole Form II can be isolated by any method known in the art.
  • the anhydrous aripiprazole Form II can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the anhydrous aripiprazole Form II.
  • the anhydrous aripiprazole Form II is dried at a temperature of about 3O 0 C to about 6O 0 C, more preferably, at a temperature of about 4O 0 C to about 53 0 C under reduced pressure.
  • Another embodiment of the invention encompasses a method of preparing anhydrous aripiprazole Form II comprising: providing a mixture of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile, butyl- acetate, dimethyl formamide (DMF), a mixture of tetrahydrofuran (THF) and IPA, water, diethyl ether (DEE) and acetone; heating the mixture at a temperature of about 45 0 C to about the reflux temperature; cooling the mixture to a temperature of about 1O 0 C to about -20 0 C; maintaining the mixture for about 15 minutes to about 60 hours to obtain anhydrous aripiprazole Form II; isolating the anhydrous aripiprazole Form II; providing a slurry of aripiprazole in a solvent selected from the group consisting of: C 3 -C 8 ketones, THF, acetonitrile
  • the aripiprazole used in the process is selected from the group consisting of: crystalline aripiprazole Form XII, Compound 2, Form C, anhydrate, hydrate, solvate and mixtures thereof.
  • the solvent is acetone.
  • the mixture is heated to a temperature of about 56 0 C.
  • the cooling is to a temperature of about 4°C.
  • the cooled mixture is maintained for about 15 hours.
  • the amount of aripiprazole Form II used for seeding is about 0.05% to 5% by weight of the starting aripiprazole.
  • the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 20:1 ml of acetone per gram of aripiprazole. More preferably, the ratio of acetone to aripiprazole in the slurry is about 3:1 to about 6:1 ml of acetone per gram of aripiprazole.
  • the slurry can be prepared using the conditions and reagents described above.
  • Aripiprazole Form II can be isolated using the methods described above.
  • Another embodiment of the invention encompasses a method of preparing aripiprazole Form II comprising: combining aripiprazole and acetone to obtain a slurry; and seeding the slurry with aripiprazole Form II.
  • the starting aripiprazole in crystalline form (30 g), acetone (90-180 ml) and aripiprazole Form II (0.015 to 1.5 g) were introduced into a 250 ml reactor.
  • the mixture was heated at 25 0 C to 5O 0 C and stirred for at least 1 hr. Then, the mixture was cooled to room temperature and stirred for at least 10 min.
  • the precipitate, wet aripiprazole Form II was collected by filtration and washed with 30 ml of acetone.
  • the wet aripiprazole Form II was dried under vacuum at 40 0 C to 53 0 C overnight. Dry aripiprazole Form II was obtained.
  • Table 1 The results are summarized in Table 1.
  • Example 14 Preparation of Aripiprazole Form II by slurry in acetone including seeding of Aripiprazole Form II
  • Aripiprazole Form XII (10.8 Kg wet or 10 Kg dry), acetone (40 L) and aripiprazole Form II (200 g) were introduced into 100 L reactor. The mixture was heated to 48 0 C and stirred for 2 hr. Then, the mixture was cooled to room temperature and stirred for 1 hour. Aripiprazole Form II was collected by filtration and washed with 10 L of acetone. The wet aripiprazole Form II was dried under vacuum at 49 0 C for 4 hours. 9.5 Kg of dry aripiprazole Form II was obtained.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
EP06825291A 2005-09-29 2006-09-29 Methods of preparing anhydrous aripiprazole form ii Withdrawn EP1934183A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72261605P 2005-09-29 2005-09-29
US72645605P 2005-10-12 2005-10-12
US73709205P 2005-11-15 2005-11-15
PCT/US2006/038279 WO2007041414A1 (en) 2005-09-29 2006-09-29 Methods of preparing anhydrous aripiprazole form ii

Publications (1)

Publication Number Publication Date
EP1934183A1 true EP1934183A1 (en) 2008-06-25

Family

ID=37670930

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06825291A Withdrawn EP1934183A1 (en) 2005-09-29 2006-09-29 Methods of preparing anhydrous aripiprazole form ii

Country Status (7)

Country Link
EP (1) EP1934183A1 (ko)
JP (1) JP2008521835A (ko)
KR (1) KR20070088750A (ko)
BR (1) BRPI0606163A2 (ko)
IL (1) IL186278A0 (ko)
MX (1) MX2007006368A (ko)
WO (1) WO2007041414A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101340214B1 (ko) * 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PL1613598T3 (pl) * 2003-12-16 2012-03-30 Teva Pharma Sposób wytwarzania krystalicznych form aripiprazolu

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007041414A1 *

Also Published As

Publication number Publication date
IL186278A0 (en) 2008-01-20
JP2008521835A (ja) 2008-06-26
MX2007006368A (es) 2007-07-11
BRPI0606163A2 (pt) 2009-05-26
WO2007041414A1 (en) 2007-04-12
KR20070088750A (ko) 2007-08-29

Similar Documents

Publication Publication Date Title
JP4700813B2 (ja) テルミサルタンの多形体、その調製方法及び医薬組成物の調製のためのその使用
EP2093217B1 (en) Process for preparing Form X of aripiprazole
CA2595334C (en) Polymorphic forms of aripiprazole and processes for making
EP2951158B1 (en) Process for the preparation of ivacaftor and solvates thereof
US9273044B2 (en) Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CA2550726A1 (en) Methods of preparing aripiprazole crystalline forms
AU2016384921A1 (en) Crystalline form of BTK kinase inhibitor and preparation method thereof
EP3337485B1 (en) Crystalline forms of ibrutinib
EP1812397A1 (en) Process of making crystalline aripiprazole
US20050277650A1 (en) Process for preparing aripirazole hydrate
EP1765782A1 (en) Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
WO2016131431A1 (en) Solid forms of empagliflozin
HRP20050039A2 (en) Crystal forms of olanzapine and processes for their preparation
EP1934183A1 (en) Methods of preparing anhydrous aripiprazole form ii
WO2015014984A1 (en) A process for preparing rifaximin k
WO2004085426A1 (en) Novel crystalline forms of candesartan cilexetil
US7714129B2 (en) Methods of preparing anhydrous aripiprazole form II
AU2012204839A1 (en) Method for resolution of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan- 1-yl)-3,3-dimethyl-piperazine
WO2011153221A1 (en) Solid state forms of ixabepilone
JP7236458B2 (ja) トリアゾロキナゾリノンの合成
WO2008130534A1 (en) Crystalline forms of topotecan hydrochloride and processes for making the same
WO2008038143A2 (en) Novel solid forms of rimonabant and synthetic processes for their preparation
US20120267533A1 (en) Processes for the preparation of form i and form ii of palonosetron hydrochloride
KR101489062B1 (ko) 고순도의 올란자핀 및 이의 결정형 ii의 제조방법
KR101340214B1 (ko) 무수 아리피프라졸 ⅱ형 결정의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080716

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120301